Related Experiment Video

Updated: May 29, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Src inhibitors are promising therapy molecules for human cervical carcinomas

Ala-Eddin Al Moustafa1, Amber Yasmeen, Amal Alachkar

  • 1Syrian Research Cancer Centre of the Syrian Society against Cancer, Aleppo, Syria. ala-eddin.almoustafa@mcgill.ca

Medical Hypotheses
|August 26, 2011
PubMed

Insights

Metastatic cervical cancer survival rates remain low. This study hypothesizes that targeting Src family kinases, often deregulated by human papillomaviruses (HPVs), could offer new treatment strategies for cervical cancer.

Area of Science:

  • Oncology
  • Virology
  • Molecular Biology

Background:

  • Metastatic cervical cancer is a leading cause of cancer mortality in women globally.
  • High-risk human papillomaviruses (HPVs) are implicated in cervical cancer progression.
  • The 5-year survival rate for cervical cancer has stagnated around 50% for two decades.

Purpose of the Study:

  • To investigate novel therapeutic strategies for metastatic cervical cancer.
  • To explore the potential of targeting Src family kinases in cervical cancer treatment.
  • To examine the role of HPV oncoproteins in deregulating Src activity.

Main Methods:

  • Review of existing literature on cervical cancer, HPV, and Src family kinases.
  • Analysis of the association between Src activity and cervical carcinoma aggressiveness.
  • Hypothesis generation based on the deregulation of Src by HPV E6/E7 oncoproteins.

Main Results:

  • Src family kinase activity is elevated in various human carcinomas, including cervical cancer.
  • Elevated Src activity correlates with more aggressive cancer phenotypes.
  • High-risk HPV oncoproteins (E6/E7) are known to deregulate Src activity in cervical cancers.

Conclusions:

  • The Src family represents a potential therapeutic target for cervical cancer treatment.
  • Further research, including preclinical and clinical studies, is warranted to validate this hypothesis.
  • Targeting Src may offer a new avenue for improving outcomes in cervical cancer patients.

More Related Videos

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates these...
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...